Investigation launched into ADMA Biologics for possible revenue inflation via channel-stuffing.

Berger Montague PC is investigating ADMA Biologics' Board for potential breaches of fiduciary duty related to alleged channel-stuffing to boost revenue despite falling demand for its main product, ASCENIV. This legal probe could impact shareholder confidence and the company's reputation. Investors interested in the case can contact Berger Montague for more information. ADMA is a biopharmaceutical firm specializing in immune deficiency treatments, headquartered in New Jersey.